ORGO Ratios | P/E, ROE & Valuation
On the Key Ratios page for ORGO (ORGO), the latest P/E shown frames valuation, while ROE indicates profitability and capital efficiency. Together with the current ratio shown and debt-to-equity shown, these signals help you judge whether valuation is supported by fundamentals across the historical rows.
Financial Performance Ratios
ORGO Historical Per Share Metrics
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Revenue per Share | ||||||
| Net Income per Share | ||||||
| Operating Cash Flow per Share | ||||||
| Free Cash Flow per Share | ||||||
| Cash per Share | ||||||
| Book Value per Share | ||||||
| Tangible Book Value per Share | ||||||
| Interest Debt per Share | ||||||
| CAPEX per Share |
ORGO Historical Valuation Ratios
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Price to Earnings (P/E) | ||||||
| Price to Book (P/B) | ||||||
| Price to Sales (P/S) | ||||||
| Enterprise Value to EBITDA | ||||||
| EV to Sales | ||||||
| EV to Operating Cash Flow | ||||||
| EV to Free Cash Flow | ||||||
| Enterprise Value |
ORGO Historical Profitability Ratios
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | ||||||
| Return on Invested Capital (ROIC) | ||||||
| Return on Tangible Assets | ||||||
| Earnings Yield | ||||||
| Free Cash Flow Yield | ||||||
| Dividend Yield |
ORGO Historical Liquidity & Financial Strength
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Current Ratio | ||||||
| Interest Coverage | ||||||
| Income Quality | ||||||
| Debt to Equity | ||||||
| Debt to Assets | ||||||
| Net Debt to EBITDA |
ORGO Historical Efficiency Ratios
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Receivables Turnover | ||||||
| Payables Turnover | ||||||
| Inventory Turnover | ||||||
| Days Sales Outstanding | ||||||
| Days Payables Outstanding | ||||||
| Days of Inventory on Hand |
ORGO Historical Market Metrics
···| Metric (FY) | ||||||
|---|---|---|---|---|---|---|
| Enterprise Value to EBITDA | ||||||
| Market Cap | ||||||
| Enterprise Value | ||||||
| Dividend Yield | ||||||
| Payout Ratio |
Related peers
Compare More →| EBS Emergent BioSolutions Inc. | $8.66 +0.00% |
| ANGO AngioDynamics, Inc. | $10.46 +1.16% |
| SNDL SNDL Inc. | $1.53 +6.25% |
| EOLS Evolus, Inc. | $4.63 +4.28% |
| R Ryder System, Inc. | $212.05 -3.54% |
| SIGA SIGA Technologies, Inc. | $4.70 +2.62% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| EBS Emergent BioSolutions Inc. | $8.66 | +0.00% | 448.34 M | 9.31 | 0.93 | 0.00% | Buy | 381 |
| ANGO AngioDynamics, Inc. | $10.46 | +1.16% | 432.20 M | -13.76 | -0.76 | 0.00% | Buy | 384 |
| SNDL SNDL Inc. | $1.53 | +6.25% | 396.58 M | -38.25 | -0.04 | 0.00% | Buy | 1.92 |
| EOLS Evolus, Inc. | $4.63 | +4.28% | 301.23 M | -5.79 | -0.80 | 0.00% | Buy | 529 |
| R Ryder System, Inc. | $212.05 | -3.54% | 8.36 B | 17.67 | 12.00 | 0.86% | Buy | 556 |
| SIGA SIGA Technologies, Inc. | $4.70 | +2.62% | 336.73 M | 14.69 | 0.32 | 25.53% | Hold | 558 |
Frequently Asked Questions
Is ORGO stock overvalued based on its P/E ratio?
On this page, you can use the latest P/E (from the Key Ratios table) as your starting point and compare it to the company's multi-year P/E range in the historical rows. When the current P/E sits near its historical average, valuation may be broadly "in line." Investors typically then focus on trend direction (whether profitability and cash-flow metrics are improving) and balance-sheet risk (liquidity and leverage) rather than treating the P/E in isolation.
What is ORGO market cap?
Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The Key Ratios table includes Market Cap so you can see the latest valuation size. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.
What is a good P/E ratio for ORGO compared to its industry?
There isn't one universal "good" P/E - P/E should be judged against the business model and expected growth for its sector. A practical approach is: (1) compare the P/E on this page to ORGO's own historical range (shown across the table's rows), and (2) benchmark against peer companies using the Screener's P/E filters and the Peers Comparison/Compare tools. If profitability (ROE/ROIC) and cash-flow strength are improving, a higher P/E can be more defensible; if returns are slipping, even a lower P/E may be a value trap.
How does ORGO compare to its competitors in key financial ratios?
The fastest way to compare ORGO with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see ORGO outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.
Is ORGO financially strong based on its ratios?
To assess whether ORGO is financially strong, review both profitability and balance-sheet risk together. Use the liquidity and leverage rows in the Key Ratios table (current ratio, interest coverage, and debt-to-equity) as your checklist for financial resilience. Then confirm the same story is supported by ROE/ROIC (quality of earnings) and by cash-flow backed metrics in the table.
What do ORGO's financial ratios say about its future growth?
Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If ORGO is sustaining strong returns (for example ROE and ROIC) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.